Soligenix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.10.22	Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting (PR Newswire)
23.09.22	Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting (PR Newswire)
08.09.22	Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
06.09.22	Soligenix: FDA Awards $2.6 Mln Orphan Products Development Grant For Study Of HyBryte To Treat CTCL (RTTNews)
06.09.22	U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
12.08.22	Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results (PR Newswire)
27.07.22	Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
25.07.22	SERB To Partner With Soligenix For Use Of Their Antigen To Accelerate Ricin Therapeutic Program (RTTNews)
25.07.22	Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen (PR Newswire)
20.07.22	HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology (PR Newswire)
28.06.22	Soligenix Gets FDA Clearance On SGX302 Phase 2a Trial In Mild-to-moderate Psoriasis (RTTNews)
28.06.22	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis (PR Newswire)
23.06.22	Soligenix's Bivalent Vaccine Provides Protection In Non-human Primates Against Marburg Marburgvirus (RTTNews)
23.06.22	Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine (PR Newswire)
01.06.22	Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified (PR Newswire)
23.05.22	Soligenix Gets US Patent Allowance For Thermostabilized Vaccine Platform (RTTNews)
23.05.22	Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform (PR Newswire)
18.05.22	Soligenix to Present at the H.C. Wainwright Global Investment Conference (PR Newswire)
13.05.22	Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results (PR Newswire)
19.04.22	Soligenix Receives $1.4M in Non-Dilutive Government Funding (PR Newswire)
29.03.22	Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results (PR Newswire)
17.03.22	Soligenix: CiVax Vaccine Demonstrates Robust Immune Responses In Mice (RTTNews)
17.03.22	Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron (PR Newswire)
02.03.22	Soligenix to Present at the Q1 Virtual Investor Summit (PR Newswire)
08.02.22	Soligenix to Present at the 2022 BIO CEO & Investor Conference (PR Newswire)
10.01.22	Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts (PR Newswire)
06.01.22	Soligenix to Present at Upcoming Investor Conferences (PR Newswire)
04.01.22	Soligenix: Dusquetide Effective At Reducing Tumor Size In Nonclinical Xenograft Models (RTTNews)
04.01.22	Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies (PR Newswire)
02.12.21	Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine (PR Newswire)
12.11.21	Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results (PR Newswire)
08.11.21	Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom (PR Newswire)
04.11.21	Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine (PR Newswire)
01.11.21	Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development (PR Newswire)
29.10.21	Pre-market Movers: RVI, ABIO, ALF, ZEN, DBVT… (RTTNews)
12.10.21	HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit (PR Newswire)
11.10.21	Pre-market Movers: TRVI, NTRB, LQDA, CEI, AVDL… (RTTNews)
28.09.21	Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates (PR Newswire)
27.09.21	Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire)
16.09.21	Soligenix to Advance Synthetic Hypericin Development in Psoriasis (PR Newswire)
09.09.21	Soligenix Reports Extension Of Hypericin Orphan Designation Beyond Cutaneous T-cell Lymphoma (RTTNews)
09.09.21	FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma (PR Newswire)
24.08.21	Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review (PR Newswire)
18.08.21	Soligenix Reports Positive Preclinical Data With Filovirus Vaccine Candidates (RTTNews)
18.08.21	Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates (PR Newswire)
13.08.21	Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results (PR Newswire)
22.06.21	HyBryte™ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting (PR Newswire)
10.06.21	Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency (PR Newswire)
09.06.21	Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program (PR Newswire)
23.12.20	CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Geberit	511.60	3.42 %	K V
UBS Group	29.99	2.08 %	K V
Logitech Intl	80.78	2.02 %	K V
Sika	221.90	1.42 %	K V
Zurich Insur Gr	536.60	1.36 %	K V
Roche Hldg G	264.50	0.42 %	K V
Novartis	90.43	0.36 %	K V
Alcon	75.90	0.26 %	K V
CieFinRichemont	139.70	-0.36 %	K V
Nestle	73.62	-0.73 %	K V

Nachrichten zu Soligenix Inc Registered Shs (Old)

Aktien Top/Flop

Meistgelesene Nachrichten